Limits...
Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Local application of bisphosphonates has been proven to be safer than systemic administration to promote implant fixation. The objective of this study was to introduce such a simple, convenient and efficient method to enhance titanium (Ti) implant osseointegration in ovariectomized (OVX) rats.

Material and methods: Twenty female Sprague-Dawley rats sequentially underwent bilateral ovariectomy and tibia implantation, and injection of 30 µg/implant zoledronic acid (ZOL) at the site of implantation was performed. At the end of the study, the tibiae, mandibles, femurs and vertebrae were harvested for dual energy X-ray absorptiometry, histology and micro-computed tomography examination.

Results: Ovariectomized rats showed poor bone density, bone mass and trabecular microstructure. OVX + ZOL rats were characterized by significantly improved peri-implant bone area (1.72-fold), bone contact (2.30-fold), bone mineral density (1.57-fold) and bone mineral content (1.67-fold), as well as moderately increased bone volume to total volume ratio (1.34-fold), percentage osteointegration (1.54-fold), connectivity density (1.45-fold), and trabecular number (1.43-fold), but decreased trabecular separation (57.69%) when compared with the control levels (p < 0.05). No histological signs of jaw osteonecrosis were observed in the rats treated with ZOL, and there was no significant difference between the OVX group and OVX + ZOL group in the bone mass of the mandible, femur and 5th lumbar vertebra (p > 0.05). In addition, the overproduction of osteoporosis-induced advanced glycation end-products (AGEs) was completely prevented by local treatment with 30 µg/implant ZOL.

Conclusions: A local, one time, low-dose injection of ZOL at the site of implantation is able to promote the osseointegration of Ti implants following postmenopausal osteoporosis, and this action may be partly mediated by inhibition of the osteoporosis-induced AGE overproduction in the bone marrow.

No MeSH data available.


Effects of local zoledronic acid (ZOL) treatment on the advanced glycation end products (AGEs) expressed in the bone marrow of the proximal tibia (original magnification 40×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016583&req=5

Figure 0005: Effects of local zoledronic acid (ZOL) treatment on the advanced glycation end products (AGEs) expressed in the bone marrow of the proximal tibia (original magnification 40×)

Mentions: Figure 5 shows the immunohistological staining of the proximal tibia from different groups. The AGE CML was seen brown in the bone marrow. In contrast, the accumulation of AGEs was significantly inversely correlated with the new bone formation around the Ti implants. OVX induced not only bone loss but also more AGE expression in vivo, while local treatment of 30 µg/implant ZOL evidently promoted peri-implant new bone formation and resulted in the downregulation of AGEs in the bone marrow. Our results indicated that the beneficial effects of ZOL local treatment on Ti implant osseointegration in OVX rats may be partly mediated by inhibition of the osteoporosis-induced AGE overproduction in the bone marrow.


Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats
Effects of local zoledronic acid (ZOL) treatment on the advanced glycation end products (AGEs) expressed in the bone marrow of the proximal tibia (original magnification 40×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016583&req=5

Figure 0005: Effects of local zoledronic acid (ZOL) treatment on the advanced glycation end products (AGEs) expressed in the bone marrow of the proximal tibia (original magnification 40×)
Mentions: Figure 5 shows the immunohistological staining of the proximal tibia from different groups. The AGE CML was seen brown in the bone marrow. In contrast, the accumulation of AGEs was significantly inversely correlated with the new bone formation around the Ti implants. OVX induced not only bone loss but also more AGE expression in vivo, while local treatment of 30 µg/implant ZOL evidently promoted peri-implant new bone formation and resulted in the downregulation of AGEs in the bone marrow. Our results indicated that the beneficial effects of ZOL local treatment on Ti implant osseointegration in OVX rats may be partly mediated by inhibition of the osteoporosis-induced AGE overproduction in the bone marrow.

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Local application of bisphosphonates has been proven to be safer than systemic administration to promote implant fixation. The objective of this study was to introduce such a simple, convenient and efficient method to enhance titanium (Ti) implant osseointegration in ovariectomized (OVX) rats.

Material and methods: Twenty female Sprague-Dawley rats sequentially underwent bilateral ovariectomy and tibia implantation, and injection of 30 µg/implant zoledronic acid (ZOL) at the site of implantation was performed. At the end of the study, the tibiae, mandibles, femurs and vertebrae were harvested for dual energy X-ray absorptiometry, histology and micro-computed tomography examination.

Results: Ovariectomized rats showed poor bone density, bone mass and trabecular microstructure. OVX + ZOL rats were characterized by significantly improved peri-implant bone area (1.72-fold), bone contact (2.30-fold), bone mineral density (1.57-fold) and bone mineral content (1.67-fold), as well as moderately increased bone volume to total volume ratio (1.34-fold), percentage osteointegration (1.54-fold), connectivity density (1.45-fold), and trabecular number (1.43-fold), but decreased trabecular separation (57.69%) when compared with the control levels (p < 0.05). No histological signs of jaw osteonecrosis were observed in the rats treated with ZOL, and there was no significant difference between the OVX group and OVX + ZOL group in the bone mass of the mandible, femur and 5th lumbar vertebra (p > 0.05). In addition, the overproduction of osteoporosis-induced advanced glycation end-products (AGEs) was completely prevented by local treatment with 30 µg/implant ZOL.

Conclusions: A local, one time, low-dose injection of ZOL at the site of implantation is able to promote the osseointegration of Ti implants following postmenopausal osteoporosis, and this action may be partly mediated by inhibition of the osteoporosis-induced AGE overproduction in the bone marrow.

No MeSH data available.